Cartesian Posts $0.38 Loss, Beats Estimates by 56 Cents as Net Loss Narrows
RNAC sits 22% above its 52-week low of $5.6 on light trading volume (0.1× avg).
Summary
Cartesian reported a Q3 adjusted loss of $0.38 per share, well better than the $0.94 loss seven analysts expected and a sharp improvement from the $1.38 loss a year ago. Revenue was zero versus roughly $114 thousand expected, so the beat is cost-driven, not commercial. Net loss narrowed to $11.5 million from $35.9 million a year ago, helped by non-cash CVR and derivative gains rather than operations. Cash of $124.7 million against a nine-month operating burn of $70.9 million gives the company at least a year of runway. The stock is down 5.4% this quarter and trades near $6.86 against a median analyst target of $38.50, so the market is not paying for the pipeline story yet.
At the time of this announcement, RNAC was trading at $6.86 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $207.4M. The 52-week trading range was $5.60 to $11.00. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Reuters.